查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球失智症运动障碍治疗症候群市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按用于治疗的药物、按地区
市场调查报告书
商品编码
1410525

全球失智症运动障碍治疗症候群市场 - 全球产业分析、规模、份额、成长、趋势、预测 (2031) - 按用于治疗的药物、按地区

Treatment Syndromes Dementia Movement Disorders Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region:
出版日期: | 出版商: Fairfield Market Research | 英文 82 Pages | 商品交期: 2-5个工作天内

价格
简介目录

近年来，治疗痴呆症和运动障碍相关综合征的全球药物市场经历了显着增长。痴呆症是一种广泛的精神疾病，以及包括帕金森氏症在内的运动障碍，给世界各地的患者和照护者带来了重大挑战。最近的数据显示，大约 80% 患有帕金森氏症等运动障碍的人最终会出现认知障碍，这进一步凸显了有效治疗的必要性。

世界各地人口老化是痴呆症患者数量增加的动力。病例激增促使医疗保健提供者探索各种解决方案，包括家庭护理服务、成人日托服务、心理治疗、药物治疗以及为晚期痴呆症患者量身定制的医疗设备。为了满足患者及其家人的需求，安宁疗护单位也大幅成长。

然而，儘管努力减轻痴呆症和运动障碍患者的负担，但仍存在一些挑战。这些挑战包括严格的监管框架、药物审批过程中的官僚障碍、缺乏研发资金以及寻找有效治疗管理的持续努力。值得注意的是，大多数旨在治疗这些疾病的药物未能通过 III 期试验，为寻找可行的治疗方法造成了困难。

该报告研究了全球痴呆症运动障碍治疗综合症市场，并提供了市场概况，包括用于治疗的药物的趋势、区域趋势以及进入市场的公司的竞争趋势。

目录

第一章执行摘要

第二章市场概况

  • 市场定义与细分
  • 市场动态
  • 价值链分析
  • 波特五力分析
  • COVID-19 影响分析
  • 乌克兰与俄罗斯衝突的影响
  • 经济概况
  • PESTLE分析

第三章全球治疗症候群、失智症与运动障碍市场展望，2018-2031

  • 全球痴呆症运动障碍治疗综合症市场前景（按用于治疗晚期痴呆症的药物划分），价值（十亿美元），2018-2031 年
  • 全球痴呆症运动障碍治疗综合症市场前景（按用于治疗伴有其他神经异常的晚期痴呆症的药物），价值（十亿美元），2018-2031 年
  • 全球痴呆症运动障碍治疗综合症市场前景（按用于治疗运动障碍综合症的药物划分），价值（美元），2018-2031 年
  • 全球治疗症候群、失智症和运动障碍市场展望，按地区、价值（十亿美元），2018-2031 年

第四章北美失智症运动障碍治疗症候群市场展望，2018-2031

第五章欧洲失智症运动障碍治疗症候群市场展望，2018-2031

第六章亚太地区失智症运动障碍治疗症候群市场展望，2018-2031

第七章拉丁美洲失智症运动障碍治疗症候群市场展望，2018-2031

第八章中东与非洲痴呆症运动障碍治疗症候群市场展望，2018-2031

第9章 竞争格局

  • 用于治疗运动障碍综合症的药物与用于治疗伴有其他神经系统异常的进行性痴呆的药物的热图
  • 2023 年公司市场份额分析
  • 竞争力仪表板
  • 公司简介
    • F. Hoffmann-La Roche, Ltd.
    • Baxter
    • Novartis AG
    • Merck & Co., Inc.
    • Sanofi
    • Pfizer, Inc.
    • Valeant Pharmaceuticals International, Inc.
    • AstraZeneca GmbH
    • Abbott Laboratories, Inc.
    • Bristol-Myers Squibb Company

第10章附录

简介目录

Leading Pharmaceutical Companies Aim to Address Rising Incidence of Cognitive Defects

The global market for the treatment of syndromes related to dementia and movement disorders has witnessed remarkable growth in recent years, as the number of individuals affected by these conditions continues to rise. Dementia, a broad category of mental illnesses, and movement disorders, including Parkinson's disease, have presented significant challenges for both patients and caregivers worldwide. According to recent data, approximately 80% of people with movement disorders such as Parkinson's ultimately develop cognitive defects, further emphasizing the need for effective treatments.

Key Market Dynamics:

The increasing aging population across the globe is a driving force behind the rising number of dementia cases. This surge in cases has prompted healthcare providers to explore a range of solutions, including home care services, adult day care services, psychological therapies, medication, and medical devices tailored for last-stage dementia patients. Palliative care units are also witnessing significant growth in response to the demands of patients and their families.

However, despite the collective efforts to ease the burden on those affected by dementia and movement disorders, several challenges persist. These challenges include a stringent regulatory framework, bureaucratic hurdles in the drug approval process, insufficient funding for research and development, and the ongoing struggle to find effective therapeutic management methods. It is noteworthy that most drugs designed to treat these conditions fail to pass Phase III testing, creating a daunting roadblock in the quest to find viable treatments.

Regional Analysis:

Geographically, the North America region is expected to maintain its dominance in the global market for the treatment of syndromes associated with dementia and movement disorders. This dominance is driven by the growing aging population and the increasing incidence of neurodegenerative diseases. Over the next six years, the Asia region is also projected to experience higher growth rates in this market, signaling the need for innovative solutions to meet the rising demand.

Key Market Players:

Major companies at the forefront of the global market for the treatment of dementia and movement disorders include Novartis AG, Sanofi S.A., AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Valeant Pharmaceutical International, and Pfizer, among others. These industry leaders are dedicated to developing innovative treatments to address the complex challenges presented by these debilitating conditions.

Segment Analysis:

The global market for the treatment of syndromes related to dementia and movement disorders is categorized based on the drugs used for treatment, including progressive dementia, movement disorders, and progressive dementia with certain other neurological abnormalities. These segments encompass drugs tailored for specific conditions, diseases-based therapeutics, and those designed to address associated neurological abnormalities.

As the global community grapples with the growing burden of dementia and movement disorders, the healthcare and pharmaceutical industries are committed to advancing research and delivering effective treatments that enhance the quality of life for affected individuals and their families.

By Drugs Used to Treatment Progressive Dementia

  • Diseases Based Therapeutics Under Progressive Dementia
  • Drugs for Progressive Dementia

By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities

  • Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
  • Drugs for Progressive Dementia

By Drugs Used to Treat Movement Disorder Syndrome

  • Diseases Based Therapeutics Under Movement Disorder Syndrome
  • Drugs for Movement Disorder Syndrome

By Region

  • North America
  • Europe
  • Asia

Table of Contents

1. Executive Summary

  • 1.1. Global Treatment Syndromes Dementia Movement Disorders Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 3.1. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 3.1.1.2. Drugs for Progressive Dementia
  • 3.2. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 3.2.1.2. Drugs for Progressive Dementia
  • 3.3. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 3.3.1.2. Drugs for Movement Disorder Syndrome
  • 3.4. Global Treatment Syndromes Dementia Movement Disorders Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 4.1. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 4.1.1.2. Drugs for Progressive Dementia
  • 4.2. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 4.2.1.2. Drugs for Progressive Dementia
  • 4.3. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 4.3.1.2. Drugs for Movement Disorder Syndrome
  • 4.4. North America Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 5.1. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 5.1.1.2. Drugs for Progressive Dementia
  • 5.2. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 5.2.1.2. Drugs for Progressive Dementia
  • 5.3. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 5.3.1.2. Drugs for Movement Disorder Syndrome
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.12. Italy Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.13. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 6.1.1.2. Drugs for Progressive Dementia
  • 6.2. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 6.2.1.2. Drugs for Progressive Dementia
  • 6.3. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 6.3.1.2. Drugs for Movement Disorder Syndrome
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.12. India Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 7.1. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 7.1.1.2. Drugs for Progressive Dementia
  • 7.2. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 7.2.1.2. Drugs for Progressive Dementia
  • 7.3. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 7.3.1.2. Drugs for Movement Disorder Syndrome
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Diseases Based Therapeutics Under Progressive Dementia
      • 8.1.1.2. Drugs for Progressive Dementia
  • 8.2. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Diseases Based Therapeutics Under Progressive Dementia with Other Neurological Abnormalities
      • 8.2.1.2. Drugs for Progressive Dementia
  • 8.3. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Diseases Based Therapeutics Under Movement Disorder Syndrome
      • 8.3.1.2. Drugs for Movement Disorder Syndrome
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 8.4.1.7. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.8. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treatment Progressive Dementia, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Treatment Syndromes Dementia Movement Disorders Market By Drugs Used to Treat Movement Disorder Syndrome, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Drugs Used to Treat Movement Disorder Syndrome vs By Drugs Used to Treat Progressive Dementia with Other Neurological Abnormalities Heat map
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. F. Hoffmann-La Roche, Ltd.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Baxter
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. Novartis AG
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Merck & Co., Inc.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Sanofi
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Pfizer, Inc.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Valeant Pharmaceuticals International, Inc.
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. AstraZeneca GmbH
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Abbott Laboratories, Inc.
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Bristol-Myers Squibb Company
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations